Home/Filings/4/0001453687-24-000130
4//SEC Filing

Miljkovic Milos 4

Accession 0001453687-24-000130

CIK 0001453687other

Filed

Nov 17, 7:00 PM ET

Accepted

Nov 18, 7:28 PM ET

Size

14.6 KB

Accession

0001453687-24-000130

Insider Transaction Report

Form 4
Period: 2024-11-14
Miljkovic Milos
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-11-14$3.23/sh+35,000$113,05053,273 total
  • Exercise/Conversion

    Common Stock

    2024-11-15$3.23/sh+20,000$64,60038,273 total
  • Sale

    Common Stock

    2024-11-14$16.13/sh35,000$564,64518,273 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-11-1435,00050,528 total
    Exercise: $3.23Exp: 2031-09-12Common Stock (35,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-11-1520,00030,528 total
    Exercise: $3.23Exp: 2031-09-12Common Stock (20,000 underlying)
  • Sale

    Common Stock

    2024-11-15$17.14/sh20,000$342,88818,273 total
Footnotes (4)
  • [F1]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.465. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The option is currently exercisable for 64,146 shares of Common Stock and becomes exercisable for the remaining 21,382 shares of Common Stock on September 13, 2025.
  • [F4]On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

Issuer

Cartesian Therapeutics, Inc.

CIK 0001453687

Entity typeother

Related Parties

1
  • filerCIK 0002000282

Filing Metadata

Form type
4
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 7:28 PM ET
Size
14.6 KB